Table III.

Clinical features and KIF20A immunoexpression in the deceased ovarian CCC patients.

Case	Age (years)	KIF20A expression	FIGO stage	Ascites volume (ml)	CA-125 (U/ml)	Chemotherapy	Residual tumor	Recurrence site	Time to relapse (mo)	OS (mo)
1	49	High	IIIc	≤100	54	P-based	None	Pelvis	6.7	88.2
2	49	High	Ic	≥1,000	373	P-based	None	Distant	41.7	64.7
3	52	High	Ic	100–1,000	41	P-based	None	PC + distant	76.8	103.3
4	53	Low	IIc	≤100	60	None	None	PC	6.6	10.6
5	40	High	Ic	100–1,000	55	TP	None	PC+RPN	7.1	13.7
6	38	Low	IIb	≤100	52	TP	None	PC	13.3	24.1
7	38	High	IIc	≤100	328	TP	None	Pelvis	16.4	40.6
8	49	Low	Ic	100–1,000	67	P-based	None	Pelvis + distant	9.1	37.5
9	27	Low	IV	≤100	NA	P-based	None	PC	8.4	8.8
10	52	High	Ic	≤100	10	TP	None	Distant	29.4	46.9
11	54	High	IV	≥1,000	890	TP	≥5 cm	Distant	8.9	8.9
12	53	High	Ic	≤100	111	TP	None	PC + distant	10.0	14.3
13	55	High	IIIc	≤100	NA	TP	≥5 cm	PC	9.1	9.1
14	55	High	IIIc	100–1,000	920	TP	None	PC	17.9	37.3
15	39	High	Ia	≤100	53	TP	None	Pelvis	19.6	49.7
16	59	High	IIIc	≥1,000	3,149	TP	None	PC	39.4	39.4
17	58	High	IIIc	≥1,000	1,012	TP	≤1 cm	PC	4.3	4.3

KIF20A, Kinesin family member 20A; CCC, clear-cell carcinoma; FIGO, International Federation of Gynecology and Obstetrics; CA-125, cancer antigen 125; OS, overall survival; P-based, conventional platinum-based chemotherapy; TP, taxane plus platinum; PC, peritoneal cavity; RPN, retroperitoneal lymph node; Distant, distant parenchymal organ; NA, not applicable.